PULSE the living trend engine
🤖 Open Intelligence Dossier available for AI agents & citation View Markdown (.md) →
◼ Archived Business

Experimental weight-loss drug eases painful knee osteoarthritis in two clinical trials

Eli Lilly's experimental triple-hormone drug retatrutide cut knee osteoarthritis pain and produced average weight loss of roughly 25% in two Phase 3 trials involving more than 1,000 adults with obesity.

9sources
9articles
7velocity
+141%since first seen
9d agofirst detected

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

The brief

Eli Lilly's investigational obesity drug retatrutide significantly reduced knee osteoarthritis pain and improved physical function in two Phase 3 trials, TRIUMPH-1 and TRIUMPH-4, according to data presented at the American College of Rheumatology Convergence 2026 meeting and published simultaneously in the New England Journal of Medicine. In TRIUMPH-4, led by Thomas Conaghan, MBBS, PhD, of the University of Leeds, 445 patients with obesity (BMI >27) and knee OA from the U.S., Canada, Mexico, Australia, and Spain were randomized to placebo or 9 mg or 12 mg weekly subcutaneous retatrutide. Baseline characteristics included mean BMI of 40.4, mean weight of 113 kg (249 lbs), 63% women, two-thirds white, and 64% with Kellgren-Lawrence grade 3 joint damage. All participants received individualized dietary counseling and a physical activity program targeting at least 150 minutes per week.

At week 68, WOMAC pain scores fell by 4.48 points with 9 mg and 4.41 points with 12 mg versus a 2.43-point decline with placebo (baseline average 5.95). Physical function scores improved by 4.14 and 4.20 points respectively versus 2.06 points with placebo. In a responder analysis, about 70% of patients in both retatrutide arms achieved a 70% reduction in WOMAC pain versus 26% on placebo. Average weight loss exceeded one-quarter of body weight at 68 weeks, with losses approaching 7% by week 8 and continuing without an obvious plateau; some patients withdrew because they considered the weight loss excessive. High-sensitivity C-reactive protein fell by half with retatrutide versus a 25% reduction with placebo, and triglycerides and non-HDL cholesterol also improved significantly.

Adverse events led to discontinuation in 13% of the 9 mg group and 18% of the 12 mg group versus 4% on placebo. Serious adverse events occurred in about 10% of retatrutide recipients versus 2% on placebo. Gastrointestinal events were most common; fatigue, dizziness, headache, urinary tract infections, and increased skin sensitivity (12% at the higher dose, none on placebo) occurred at two to four times the placebo rate. Conaghan noted adverse events appeared more common in patients with BMI

A second Northwestern University-led trial, described by corresponding author Dr. Thomas Schnitzer of Feinberg School of Medicine, similarly showed average weight loss up to 25% and around two-thirds of active-treatment recipients reporting at least a 50% reduction in knee OA pain, while placebo recipients self-reported a 38% reduction. Schnitzer said, "The findings are really saying for people who are overweight and have OA, if you lose a significant amount of weight with this treatment, there is a good chance that you're going to get a meaningful reduction in your knee pain." He added that many participants lost considerable weight, "with a few losing up to a hundred pounds or more." Both Schnitzer and the NEJM authors emphasized that mechanisms beyond mechanical unloading — such as potential anti-inflammatory effects of GLP-1 receptor agonists — remain unclear and require further study, including whether metabolically normal OA patients could benefit without unhealthy weight loss. Retatrutide is a triple agonist of GLP-1, glucagon, and GIP receptors, a mechanism distinct from single- or dual-agonist drugs such as semaglutide and tirzepatide. It currently has FDA approval only for compassionate use, reportedly granted to just one American. Eli Lilly highlighted the data alongside updates for Zepbound (tirzepatide) and Taltz (ixekizumab) at the ACR meeting.

Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 8d ago.

Quick answers

How much weight did participants lose on retatrutide in the trials?

Participants lost on average up to 25% of their body weight after 68 weeks, with losses approaching 7% by week 8 and continuing without a clear plateau; some individuals lost 100 pounds or more.

What were the pain relief results for knee osteoarthritis?

WOMAC pain scores fell by 4.48 points (9 mg) and 4.41 points (12 mg) versus 2.43 points with placebo at week 68; about 70% of retatrutide recipients achieved a 70% pain reduction compared with 26% on placebo.

What side effects were reported with retatrutide?

Discontinuation due to adverse events occurred in 13% (9 mg) and 18% (12 mg) versus 4% placebo; serious adverse events in ~10% versus 2%. Common events included gastrointestinal symptoms, fatigue, dizziness, headache, urinary tract infections, and increased skin sensitivity (12% at 12 mg, none on placebo).

Coverage (9)

Topics

Related trends

▲ Peaking Business

The GLP-1 boom has a dark side

FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.

5 sources 5 articles v 14 1d ago
\n \n \n \n \n \n \n